Identifying the Indications & Disease Stages Most Likely to Benefit from Complement-Based Therapies to Expand Scope of Treatment
9:00 am - Tuesday 8th December 2026
Whilst complement dysregulation is observed across a broad range of diseases, it remains unclear where complement therapeutics can deliver maximum benefit to patients whilst maintaining healthy immune function.
This workshop will cover:
- Evaluating which indications offer the greatest opportunity for complement intervention and determining where complement biology is most likely to translate into meaningful patient benefit
- Debating the role of complement therapies in acute versus chronic disease settings and identifying how dosing strategies and endpoints may differ between the two
- Exploring the potential for complement therapeutics beyond orphan diseases, including how to position complement modulation within complex, multifactorial conditions where complement is not the primary disease driver, as well as the potential of complement in oncology
- Assessing when complement intervention should occur within the patient journey, including optimal treatment windows, sustainable dosing regimens and approaches to maximizing long-term therapeutic impact
